Loading…
Loading…
CAPL and GLP bring distinct strengths in income, scale, leverage and valuation, setting up a closer comparison for energy MLP investors.
ACCG-2671 (oral small molecule amylin receptor agonist) demonstrated a ~6-day half-life, no serious adverse events, and evidence of target engagement including up to 3.3% body weight loss in Phase 1/2a SAD clinical trial First participants dosed with ACCG-2671 in the 12-week MAD portion of the Phase 1/2a clinical trial; topline data expected in 1H 2027 Aleniglipron (oral small molecule selective GLP-1 receptor agonist) demonstrated up to 16.2% mean reduction in body weight at 72 weeks with no observed plateau, and improved tolerability with a 2.5 mg starting dose, including less than 5% study-drug discontinuation rates due to adverse events in the ACCESS OLE clinical trial ACCOMPLISH-1 and ACCOMPLISH-2 registrational Phase 3 clinical trials for aleniglipron enrollment ongoing; topline data expected in 2H 2028 Company to host conference call today at 8:30 a.m. ET SAN FRANCISCO, Sept.
Generating stronger distributable cash flow in their latest quarters, these high-yield energy stocks remain worthy of consideration for income-focused investors.
Global Partners (GLP) could produce exceptional returns because of its solid growth attributes.
Eli Lilly and Company TodayLLYEli Lilly and Company$1,171.40 +11.40 (+0.98%) As of 11:00 AM Eastern This is a fair market value price provided by Massive. Learn more.52-Week Range$712.05▼$1,292.65Dividend Yield0.59%P/E Ratio39.28Price Target$1,292.18Add to WatchlistOn Aug. 31, Eli Lilly & Co. NYSE: LLY announced its intention to acquire Merida Biosciences for $2.875 billion.
Citi has reiterated its 'sell' rating on Novo Nordisk (NYSE:NVO), the Danish pharmaceutical group, with a price target of 265 Danish krone against a last close of 292.4 Danish krone. Analyst Emmanuel Papadakis published Citi's weekly IQVIA tracker of Novo's GLP-1 assets, using retail prescription data up to 21 August 2026.
The U.S. Food and Drug Administration (FDA) on Tuesday warned patients and healthcare providers about severe health risks linked to unapproved and compounded glucagon-like peptide-1 (GLP-1) weight-loss medications.
Fractyl Health NASDAQ: GUTS outlined a commercial strategy for its investigational Revita procedure, positioning the one-time endoscopic therapy as a potential option for patients seeking to maintain weight loss after discontinuing GLP-1 medicines.